Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis

  • Navina L. Chrobok,
  • John G. J. M. Bol,
  • Cornelis A. Jongenelen,
  • John J. P. Brevé,
  • Said El Alaoui,
  • Javier Fidalgo-Lopez,
  • Guy Fournet,
  • Benoît Joseph,
  • Micha M. M. Wilhelmus,
  • Benjamin Drukarch,
  • Anne-Marie van Dam

Correction: Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis

  • Navina L. Chrobok, 
  • John G. J. M. Bol, 
  • Cornelis A. Jongenelen, 
  • John J. P. Brevé, 
  • Said El Alaoui, 
  • Javier Fidalgo-Lopez, 
  • Guy Fournet, 
  • Benoît Joseph, 
  • Micha M. M. Wilhelmus, 
  • Benjamin Drukarch
PLOS
x
  • Article
  • Metrics
  • Comments
  • Media Coverage

Dr. Javier Fidalgo-Lopez, Dr. Guy Fournet, and Dr. Benoît Joseph are not included in the author byline. The contributions of these authors are as follows: Design and synthesis of BJJF078. Please view the correct author byline, affiliations, and citation here:

Navina L. Chrobok1, John G. J. M. Bol1, Cornelis A. Jongenelen1, John J. P. Brevé1, Said El Alaoui2, Javier Fidalgo-Lopez2, 3☯, Guy Fournet3☯, Benoît Joseph3☯, Micha M. M. Wilhelmus1, Benjamin Drukarch1, Anne-Marie van Dam1

☯ These authors contributed equally to this work.

1 Department of Anatomy and Neurosciences, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands, 2 Covalab, Villeurbanne, France, 3 Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, Université Claude Bernard—Lyon 1, Villeurbanne, France

Chrobok NL, Bol JGJM, Jongenelen CA, Brevé JJP, El Alaoui S, Fidalgo-Lopez J, et al. (2018) Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis. PLoS ONE 13(4): e0196433. https://doi.org/10.1371/journal.pone.0196433

There is an error in the fifth sentence of the Materials and methods section under the subheading “Inhibition of recombinant Transglutaminase activity”. The correct sentence is: The two lyophilized TG2 inhibitors (see Fig 1 for chemical structure) BJJF078 (3,4-Dimethoxy-N-(5-[4-(acryloylamino)piperidine-1-sulfonyl]-naphthalen-1-yl)-benzamide, see S1 Appendix, synthetized and provided by Covalab, Villeurbanne, France and Institut de Chimie et Biochimie Moléculaires et Supramoléculaires, Villeurbanne, France) and ERW1041E (2-[(3-Bromo-4,5-dihydro-isoxazol-5-ylmethyl)-carbamoyl]-pyrrolidine-1—carboxylic acid quinolin-3-ylmethyl ester, kindly provided by Prof C. Khosla, Stanford University, USA) [18, 22, 23] were dissolved in DMSO (stock solution: 54 mM) and stored at -80°C.

thumbnail
Fig 1. ERW1041E and BJJF078: Name and chemical structure of the TG2 inhibitors.

https://doi.org/10.1371/journal.pone.0209522.g001

In Fig 1, the heading BJFF078 should be BJJF078. The authors have provided a corrected version here.

Supporting information

S1 Appendix. Description of the synthesis of compound BJJF078.

https://doi.org/10.1371/journal.pone.0209522.s001

(DOCX)

Reference

  1. 1. Chrobok NL, Bol JGJM, Jongenelen CA, Brevé JJP, El Alaoui S, Wilhelmus MMM, et al. (2018) Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis. PLoS ONE 13(4): e0196433. https://doi.org/10.1371/journal.pone.0196433 pmid:29689097